Science as a launch driver.

An international pharmaceutical company with a German commercial unit faced a sensitive transition. The Medical Director Germany had relocated their centre of life; the geographic distance to the German entity's headquarters made continuing in the role impractical in the medium term.

At the same time, the market environment for menopausal hormone therapy was undergoing a remarkable reassessment. The lingering uncertainty from the Women's Health Initiative shaped prescribing behaviour in Germany for a long time; the treatment rate stands at around 18 percent of symptomatic women, and the AWMF S3 guideline on peri- and postmenopause is far from operationalised in every practice. At the same time, the international evidence is correcting the picture: the German Menopause Society openly speaks of a renaissance of differentiated, individualised HRT, and the FDA removed the black-box warning for oestrogen products at the end of 2025.

On the commercial level, the logic of the business is shifting in parallel. Established hormone-therapy compounds are broadly genericised, generic estradiol and progesterone products dominate the market, and the generics share in hormone therapies exceeds 78 percent. Under § 129 SGB V, pharmacies are obliged to preferentially dispense the rebate medicine of the respective health insurer. The aut-idem exclusion is only permitted in medically justified individual cases. The originator thereby loses the direct lever over the prescribing decision at the point of sale.

It was precisely into this constellation that the German subsidiary was planning the launch of an indication extension and, in parallel, the medium-term entry into a second business field: an accompanying digital health application for menopausal symptom tracking and therapy support, designed for a later fast-track submission under § 139e SGB V to the BfArM.

A delayed or wrong appointment would have hit the company in three dimensions at once. First, in the core business: the upcoming product launch hinges on the quality of the scientific preparation, on the involvement of the medical societies, on the advisory-board architecture and on the activation of the MSL team toward a physician community that, after two decades in the WHI shadow, is only now rebuilding trust in modern hormone therapy. Without medical leadership, a launch without scientific backing looms, with direct consequences for prescribing dynamics and market share.

Second, in the KOL network: leading opinion formers in women's health are personally, not institutionally, bound. The departure of a respected Medical Director without an adequate successor would have severed lines of dialogue built up over years and weakened access to congresses, guideline work and publications.

Third, in the digital strategy: the planned entry into DiGA requires a foundation of clinical evidence, study design, health-services research and medical validation that first has to be built. A DiGA for menopausal complaints stands or falls with the proof of a positive care effect under the DiGAV, and it is precisely this foundation that a Medical Director must take scientific responsibility for, long before any application is even submitted to the BfArM. A wrong hire would have damaged not only the Rx launch but also the medium-term digital agenda, with corresponding investment risk.

The company had only just completed a generational change at its helm. They were not looking for a leader to administer the status quo, but for a medical personality ready to take the company into its next phase, with the courage to walk new paths and to actively shape the transition between the classic Rx business and digital care. ANDRIS Consulting therefore set up the mandate as a senior-management mandate with three equally weighted requirement dimensions: professional fit to the task ahead, personal roots in the region and cultural connectability to a family business in generational change.

The professional dimension addressed a constellation that has long been reality in this market segment. Established compounds are broadly in generic competition, and the pharmacist is obliged to dispense the rebate medicine. For the Medical Affairs function this means a paradigm shift in everyday work. Differentiation can no longer be driven by the original clinical evidence alone, but demands a care-oriented evidence logic: real-world evidence, registry data, patient-reported outcomes, adherence studies, quality of life, differentiation via galenics and ease of use. At the same time, stakeholder work is shifting. KOL engagement in the classic sense remains important but no longer suffices when the physician's prescribing decision is effectively steered by substitution rules and reference prices. Medical Affairs becomes the interface between science, payers, health-services research and patient organisations. Added to this is the preparation of the Rx launch in a new indication and the scientific build-up of the evidence architecture for the later DiGA perspective under § 139e SGB V. ANDRIS Consulting therefore deliberately focused the search on candidates from a corporate environment where structured Medical Affairs processes, professional lifecycle management, real-world-evidence build-up and launch excellence are part of everyday work.

The regional dimension was decisive for sustainability in this mandate. Our experience as pharma headhunters shows that a leader's private situation often decides more about the long-term success of an appointment than the finest professional detail. It was precisely the predecessor who had ultimately given up the mandate due to a private relocation of their centre of life within Germany. This experience from the client's own house fed directly into the requirement profile. We therefore addressed exclusively candidates who are privately rooted in the region of the German commercial headquarters in a rural setting, with established family and social ties that make a long-term commitment realistic.

The cultural dimension was the most sensitive in an owner-led company in generational change. The new leadership sought a Medical Director who respects the diligence and value orientation of a family business while making use of the creative latitude of short decision paths. In the selection process, ANDRIS Consulting therefore assessed not only professional suitability and leadership competence, but systematically considered the candidates' overall situation: biography, private roots, prior cultural imprint in a corporate environment, willingness to help shape things in family-led mid-sized business. Our conviction as a specialised pharma recruitment firm: senior-management appointments only succeed when professional background, private situation, leadership personality and corporate culture fit simultaneously. Any one of these factors alone is not enough; all four together make an appointment sustainable.

ANDRIS Consulting won a medical leadership personality who comes from a corporate environment, brings professional Medical Affairs processes and has experience with evidence-based positioning in a therapeutic area burdened by legacy studies under increasing generic pressure. Privately rooted in the region of the German commercial headquarters, culturally connectable to a family business in generational change.

The Rx launch in the new indication could be prepared without disruption. Advisory boards were newly set up with key KOLs, expert-circle communication was calibrated to the updated evidence, the MSL team was trained on the new data basis and the involvement in the guideline work of the DGGG and DMG was stabilised. In parallel, the originator's scientific differentiation logic was newly sharpened in the generics-shaped environment, with real-world-evidence initiatives and a clearly care-oriented line of argument toward medical societies and payers. The orderly handover avoided a break in the KOL relationships.

Under the new medical leadership, the scientific foundation for the planned DiGA was also laid. Study design, endpoint architecture and considerations for proving the positive care effect under § 139e SGB V were set up, and collaboration with health-services researchers and potential study centres was initiated. The fast-track submission to the BfArM remains a medium-term undertaking that is being prepared under the medical responsibility of the new leadership.

The mandate to ANDRIS Consulting thus not only resolved the acute succession question, but enabled the German entity to pursue the Rx launch, the defence of the originator position in the market under generic pressure and the digital business build-up under coherent medical leadership.